SIMCERE PHARMA(02096.HK): PD-1/VEGF Bispecific Antibody SIM0689 Approved for Clinical Trials by NMPA
NewTimeSpace News: Simcere Pharmaceutical Group Limited (02096.HK) announced that SIM0689, a self-developed PD-1/VEGF-targeted bispecific antibody, has obtained the clinical trial approval notice issued by the National Medical Products Administration. Clinical trials for advanced solid tumors are planned. By relieving tumor-induced immune suppression and inhibiting angiogenesis, SIM0689 has demonstrated prominent anti-tumor efficacy even at low doses in multiple humanized mouse efficacy models.
NewTimeSpace News: Simcere Pharmaceutical Group Limited (02096.HK) issued a voluntary announcement on June 12, 2026. SIM0689, a bispecific antibody targeting PD-1/VEGF independently developed by the Group, has been granted the drug clinical trial approval notice by the National Medical Products Administration.
SIM0689 is a bispecific antibody that targets specific epitopes of programmed death receptor 1 (PD-1) and vascular endothelial growth factor (VEGF) simultaneously. It exerts potent anti-tumor activity by alleviating immune suppression of tumor cells and blocking angiogenesis. In various humanized mouse efficacy models, SIM0689 delivers excellent anti-tumor effects at low doses and shows overall superior efficacy compared with similar molecules, indicating broad application prospects in the treatment of a variety of solid tumors.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
